ReviewOncology reports2021
Metastatic pancreatic cancer: Mechanisms and detection (Review).
Review in Oncology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Necroptosis in pancreatic cancer: Molecular mechanisms and therapeutic implications.Apoptosis : an international journal on programmed cell death · 2026Pooled it
- Sonocavitation therapy for pancreatic cancer: Research progress, clinical application and future perspectives.iScience · 2026Review
- Targeting orthotopic and metastatic pancreatic cancer with allogeneic stem cell-engineered mesothelin-redirected CAR-NKT cells.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- S100 Calcium-Binding Protein P and Cathepsin E as Key Mediators in Pancreatic Cancer Tumorigenesis.Biomedicines · 2025Article
- Oligometastatic pancreatic cancer: current state of management and emerging therapies.The oncologist · 2025Review
- Application and prospects of ultrasound combined with immunotherapy in cancer treatment of intensive care.Frontiers in immunology · 2025Review
- Development of a Nomogram Integrating Modified Inflammation-Based Indexes for Predicting Overall Survival in Pancreatic Cancer: A Retrospective Study.Journal of inflammation research · 2025Article
- The impact of metastatic sites on survival Rates and predictors of extended survival in patients with metastatic pancreatic cancer.Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] · 2024Article
- Nanocarrier mediated entinostat and oxaliplatin combination therapy displayed enhanced efficacy against pancreatic cancer.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2024Article
- The bacterial metabolite, lithocholic acid, has antineoplastic effects in pancreatic adenocarcinoma.Cell death discovery · 2024Article
- Design, Synthesis, and Antitumor Evaluation of an Opioid Growth Factor Bioconjugate Targeting Pancreatic Ductal Adenocarcinoma.Pharmaceutics · 2024Article
- CSTF2T facilitates pancreatic adenocarcinoma growth and metastasis by elevating H3K4Me1 methylation of CALB2 via ASH2L.Cancer biology & therapy · 2023Article
- Management of Metastatic Pancreatic Cancer-Comparison of Global Guidelines over the Last 5 Years.Cancers · 2023Review
- Elastic modulus-reflected liver lesion stiffness relates to worse prognosis in pancreatic cancer patients with liver metastasis.World journal of surgical oncology · 2023Article
- Dissimilar survival and clinicopathological characteristics of mucinous adenocarcinoma located in pancreatic head and body/tail.World journal of gastrointestinal surgery · 2023Article
- Highly Selective Targeting of Pancreatic Cancer in the Liver with a Near-Infrared Anti-MUC5AC Probe in a PDOX Mouse Model: A Proof-of-Concept Study.Journal of personalized medicine · 2023Article
- Unveiling the intricate causal nexus between pancreatic cancer and peripheral metabolites through a comprehensive bidirectional two-sample Mendelian randomization analysis.Frontiers in molecular biosciences · 2023Article
- Landmarks in pancreatic cancer studies.Cancer cell international · 2022Review
- Oxidative Stress Markers Are Associated with a Poor Prognosis in Patients with Pancreatic Cancer.Antioxidants (Basel, Switzerland) · 2022Article
- Pevonedistat Suppresses Pancreatic Cancer GrowthFrontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer (PC) is a lethal malignancy. Its prevalence rate remains low but continues to grow each year. Among all stages of PC, metastatic PC is defined as late‑stage (stage IV) PC and has an even higher fatality rate. Patients with PC do not have any specific clinical manifestations. Most cases are inoperable at the time‑point of diagnosis. Prognosis is also poor even with curative‑intent surgery. Complications during surgery, postoperative pancreatic fistula and recurrence with metastatic foci make the management of metastatic PC difficult. While extensive efforts were made to improve survival outcomes, further elucidation of the molecular mechanisms of metastasis poses a formidable challenge. The present review provided an overview of the mechanisms of metastatic PC, summarizing currently known signaling pathways (e.g. epithelial‑mesenchymal transition, NF‑κB and KRAS), imaging that may be utilized for early detection and biomarkers (e.g. carbohydrate antigen 19‑9, prostate cancer‑associated transcript‑1, F‑box/LRR‑repeat protein 7 and tumor stroma), giving insight into promising therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.